Metabolomics Approach After Acute Intake of Grumixama Juice

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Dietary Supplement: Intake of grumixama juice

• Registration Number: NCT02790658
• Lead Sponsor: University of Sao Paulo

Brief Summary

Investigate the bioavailability of the main flavonoid, their colonic transformation and untargeted metabolites by an metabolomic approach following acute intake of a grumixama juice by humans.

Detailed Description

The grumixama is a sweet and little cherry native of the South and Southeast regions of the Atlantic Forest of Brazil rich in phenolic compounds, mainly anthocyanins and ellagitannins. The objective of this study is Investigate the bioavailability of the main flavonoid, their colonic transformation and untargeted metabolites by an metabolomic approach following acute intake of a grumixama juice by humans.

Fifteen healthy subjects consumed grumixama juice at single dose, and urine and plasma samples were collected at different time points over 24 h period. The metabolites were analyzed by LC-ESI-MSn, LC-Q-TOF plasma and urine were also analyzed using untargeted metabolomic approach for amino acids and organic acids by GCMS.

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2014-03
• Primary Completion: 2014-08
• Study Completion: 2016-03
• Study First Submitted: 2016-04-02
• Status Verified: 2016-05
• Study First Submitted QC: 2016-05-30
• Study First Posted: 2016-06-06
• Last Update Submitted: 2016-06-13
• Last Update Posted: 2016-06-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 15

Inclusion Criteria

• Not have medical historical of cardiovascular, gastrointestinal, hepatic, renal, thyroid and/or diabetes dysfunction
• Not be alcohol addicts, not use vitamins and other supplements
• Not are using any kind of medication which affect the digestion and absorption of food, not be smokers
• Not are pregnant.

Read More

Exclusion Criteria

• Have medical historical of cardiovascular, gastrointestinal, hepatic, renal, thyroid and/or diabetes dysfunction
• Be alcohol addicts, use vitamins and other supplements
• Are using any kind of medication which affect the digestion and absorption of food, be smokers
• Are pregnant.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Grumixama Juice	Intake of grumixama juice	Juice of grumixama purple fruit (Eugenia brasiliensis Lam.), which is good source of anthocyanins and ellagitannins. It was made with filtered water and sanitized fruits, with a blender. It was administered in single dose of 0.97 mg of anthocyanins and of 4.71 mg of ellagitannins per mL of juice. Which volunteers ingested 10 mL of juice per each Kg body weight. The metabolomic approach of plasma and urine samples following acute intake of grumixama juice was done by the collection of blood samples and urine, following the intake of grumixama juice.

Primary Outcome Measures

Name	Time	Method
Identification of metabolites in plasma and urine samples of 15 healthy volunteers after intake of grumixama juice by GCMS.	2 months	The samples were collected as describe in "Arms and Interventions", but for urine samples were used only the samples collected at times 0 (before the juice intake), 0-1h, 1-2h, 2-4h and at 24h after intake. The plasma samples had their proteins precipitated with cold methanol, the metabolites were extracted, concentrated and the amino acids and organic acids were derivatized to became volatile and the samples were analyzed by GCMS. For urine samples the procedures were similar. The mass fragment profile of derivatized compounds were compared to a GCMS library.
Identification of metabolites in plasma and urine samples of 15 healthy volunteers after intake of grumixama juice by LCMS	2 months	The blood and urine samples were collected in the times describe in "Arms and Interventions". The samples were acidified and the anthocyanins and ellagitannins metabolites were extracted by SPE column, these metabolites extracted were concentrated and analyzed by LC-ESI-MSn (for phenolic acids and anthocyanins) and LC-Q-TOF (for urolithins), the mass fragments were expressed in m/z.

Secondary Outcome Measures

Name	Time	Method
Pathway analysis of metabolites identified by GCMS	1 month	The samples were collected as describe in "Arms and Interventions", but for urine samples were used only the samples collected at times 0 (before the juice intake), 0-1h, 1-2h, 2-4h and at 24h after intake. The plasma samples had their proteins precipitated with cold methanol, the metabolites were extracted, concentrated and the amino acids and organic acids were derivatized to became volatile and the samples were analyzed by GCMS. For urine samples the procedures were similar. The mass fragment profile of derivatized compounds were compared to a GCMS library.
Identification of anthocyanins in urine samples of 10 healthy volunteers by LCMS.	2 months	The blood and urine samples were collected in the times describe in "Arms and Interventions". The samples were acidified and the anthocyanins metabolites were extracted by SPE column, these metabolites extracted were concentrated and analyzed by LC-ESI-MSn (for phenolic acids and anthocyanins) the mass fragments were expressed in m/z.
Urinary creatinine values of 15 healthy volunteers for data normalization	15 days	The creatinine was measured in the 15 volunteers by using a commercial kit, the results obtained in mg/dL, and these values were transformed in mol/L. The values of creatinine were used to normalize the quantification data.
Multivariate data analysis of metabolites identified in plasma and urine of 15 healthy volunteers after intake of grumixama juice by GCMS	2 months	The peak intensity of each compound identified by GCMS were normalized by using a internal standards (D4-alanine). For urine these data also were normalized by creatinine values to normalize sample volume. Multivariate data analysis were done observe changes in these metabolites (amino acids and organic acids) during the 24h after grumixama juice intake. The data were analyzed by MetaboAnalyst 3.0 (http://www.metaboanalyst.ca/).
Identification of urolithins in urine samples of 10 healthy volunteers by LCMS	2 months	The urine samples were collected in the times describe in "Arms and Interventions". The samples were acidified and the ellagitannins metabolites were extracted by SPE column, these metabolites extracted were concentrated and analyzed by LC-Q-TOF (for urolithins), the mass fragments were expressed in m/z.
The total elimination of anthocyanins in urine of 10 healthy volunteers after intake of grumixama juice	1 month	The total elimination amount of anthocyanins was calculated using the urine volume and it was expressed in nmol.
Identification of phenolic acids in plasma and urine samples of 10 healthy volunteers by LCMS	2 months	The blood and urine samples were collected in the times describe in "Arms and Interventions". The samples were acidified and the anthocyanins metabolites were extracted by SPE column, these metabolites extracted were concentrated and analyzed by LC-ESI-MSn (for phenolic acids and anthocyanins) the mass fragments were expressed in m/z.
Quantification of anthocyanins in urine samples of 10 healthy volunteers by HPLC	2 months	The urine samples were collected in the times describe in "Arms and Interventions". The samples were acidified and the anthocyanins metabolites were extracted by SPE column, these metabolites extracted were concentrated and analyzed by HPLC, the results were expressed nmol/mol of creatinine for urine samples. It was made to each volunteer, in each point of collection sample.
Quantification of urolithins in urine samples of 10 healthy volunteers by HPLC	2 months	The urine samples were collected in the times describe in "Arms and Interventions". The samples were acidified and the ellagitannins metabolites were extracted by SPE column, these metabolites extracted were concentrated and analyzed by HPLC, the results were expressed in mmol/mol of creatinine. It was made to each volunteer, in each point of collection sample.
Pharmacokinetic parameters (AUC) of phenolic acids in urine of 10 healthy volunteers after intake of grumixama juice	1 month	Using the quantification results for each collection time was calculated the area under curve (AUC) of phenolic acids in urine (expressed in mmol/h).
Urine volume	1 day	The volume of each urine sample was measured in mL.
The total elimination of urolithins in urine of 10 healthy volunteers after intake of grumixama juice	1 month	The total elimination amount of urolithins was calculated using the urine volume and it was expressed in µmol.
Cycle cell analysis in breast cancer cells treated with metabolites extracted from plasma and urine of 10 healthy volunteers after grumixama juice intake	2 days	Plasma and urine preparations were obtained by SPE extraction were dried and tested against breast cancer cells (MDA-MB 231) MDA-MB 231 cells were cultured in monolayer on Dulbecco Eagle modified culture medium supplemented with 10% fetal bovine serum, it was used 5x10-4 cells per well. The cells were incubated in a humidified chamber including 5% CO2 at 37ºC into a confluence of approximately 80%. Cells were further exposed to 200 mg/mL of urine and plasma extract preparations and phenolic compound standards (PCA, VA, HA, C3G) at 0.25 and 25 mg/mL, and maintained at 37ºC, under an atmosphere of 5% CO2 for 48 hours. Negative control was supplied with growth media and DMSO, and blank wells containing growth media only.; The cells were lysed, the RNA were degraded and the DNA were marked with propidium iodide (1mg/mL) and the fluorescence was measure by flow cytometer and the cell cycle analysis were done by FlowJo. The results were expressed in % of cell for each cell cycle phase.
Quantification of phenolic acids in urine samples of 10 healthy volunteers by HPLC	2 months	The urine samples were collected in the times describe in "Arms and Interventions". The samples were acidified and the anthocyanins metabolites were extracted by SPE column, these metabolites extracted were concentrated and analyzed by HPLC, the results were expressed in mmol/mol of creatinine for urine samples. It was made to each volunteer, in each point of collection sample.
Pharmacokinetic parameters (AUC) of urolithins in urine of 10 healthy volunteers after intake of grumixama juice	1 month	Using the quantification results for each collection time was calculated the area under curve (AUC) of urolithins in urine (expressed in mmol/h).
The total elimination of phenolic acids in urine of 10 healthy volunteers after intake of grumixama juice	1 month	The total elimination amount of phenolic acids was calculated using the urine volume and it was expressed in µmol.
Antiproliferative activity of metabolites extracted from urine of 10 healthy volunteers after grumixama juice intake	2 days	Urine preparations were obtained by SPE extraction were dried and tested against breast cancer cells (MDA-MB 231) MDA-MB 231 cells were cultured in monolayer on Dulbecco Eagle modified culture medium supplemented with 10% fetal bovine serum, it was used 5x10-4 cells per well. The cells were incubated in a humidified chamber including 5% CO2 at 37ºC into a confluence of approximately 80%. Cells were further exposed to 200 mg/mL of urine extract preparations and phenolic compound standards (PCA, VA, HA, C3G) at 0.25 and 25 mg/mL, and maintained at 37ºC, under an atmosphere of 5% CO2 for 48 hours. Negative control was supplied with growth media and DMSO, and blank wells containing growth media only. Cells were marked with CFSE, and fluorescence was measured by flow cytometer. The results were expressed as % of proliferation inhibition
Quantification of amino acids identified by GCMS	1 month	Standards curves of the amino acids that changed significantly after grumixama juice intake were made by GCMS. Through these standards curves the amino acids and organic acids were quantified and the results were expressed in mmol/μmol of creatinine for urine samples and mmol/mL of plasma.
Antiproliferative activity of metabolites extracted from plasma of 10 healthy volunteers after grumixama juice intake	2 days	Plasma preparations were obtained by SPE extraction were dried and tested against breast cancer cells (MDA-MB 231) MDA-MB 231 cells were cultured in monolayer on Dulbecco Eagle modified culture medium supplemented with 10% fetal bovine serum, it was used 5x10-4 cells per well. The cells were incubated in a humidified chamber including 5% CO2 at 37ºC into a confluence of approximately 80%. Cells were further exposed to 200 mg/mL of plasma extract preparations and phenolic compound standards (PCA, VA, HA, C3G) at 0.25 and 25 mg/mL, and maintained at 37ºC, under an atmosphere of 5% CO2 for 48 hours. Negative control was supplied with growth media and DMSO, and blank wells containing growth media only. Cells were marked with CFSE, and fluorescence was measured by flow cytometer. The results were expressed as % of proliferation inhibition.
Quantification of organic acids identified by GCMS	1 month	Standards curves of organic acids that changed significantly after grumixama juice intake were made by GCMS. Through these standards curves the organic acids were quantified and the results were expressed in mmol/μmol of creatinine for urine samples and mmol/mL of plasma.
Quantification of phenolic acids in plasma samples of 10 healthy volunteers by HPLC	2 months	The blood samples were collected in the times describe in "Arms and Interventions". The samples were acidified and the anthocyanins metabolites were extracted by SPE column, these metabolites extracted were concentrated and analyzed by HPLC, the results were expressed in μmol/mL of plasma. It was made to each volunteer, in each point of collection sample.
Pharmacokinetic parameters (AUC) of anthocyanins in urine of 10 healthy volunteers after intake of grumixama juice	1 month	Using the quantification results for each collection time was calculated the area under curve (AUC) of anthocyanins in urine (expressed in μmol/h).